New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - everolimus 5mg;  ;   - tablet - 5 mg - active: everolimus 5mg     excipient: butylated hydroxytoluene crospovidone hypromellose lactose lactose monohydrate magnesium stearate - the treatment of patients with subependymal giant cell astrocytoma (sega) associated with tuberous sclerosis complex (tsc) who require therapeutic intervention but are not amenable to surgery. the evidence is based on change in sega volume. further clinical benefit, such as improvement of disease-related symptoms, has not been demonstrated.

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - rivastigmine tartrate 2.4mg equivalent 1.5 mg rivastigmine;   - capsule - 1.5 mg - active: rivastigmine tartrate 2.4mg equivalent 1.5 mg rivastigmine   excipient: colloidal silicon dioxide gelatin hypromellose iron oxide yellow magnesium stearate microcrystalline cellulose tekprint red sw-1102 titanium dioxide - indicated in the treatment of patients with mild to moderately severe dementia of the alzheimer type, also termed probable alzheimers disease or alzheimers disease.

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - rivastigmine tartrate 4.8mg equivalent 3 mg rivastigmine;   - capsule - 3 mg - active: rivastigmine tartrate 4.8mg equivalent 3 mg rivastigmine   excipient: colloidal silicon dioxide gelatin hypromellose iron oxide red iron oxide yellow magnesium stearate microcrystalline cellulose tekprint red sw-1102 titanium dioxide - indicated in the treatment of patients with mild to moderately severe dementia of the alzheimer type, also termed probable alzheimers disease or alzheimers disease.

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - rivastigmine tartrate 7.2mg equivalent to 4.5 mg rivastigmine;   - capsule - 4.5 mg - active: rivastigmine tartrate 7.2mg equivalent to 4.5 mg rivastigmine   excipient: colloidal silicon dioxide gelatin hypromellose iron oxide red iron oxide yellow magnesium stearate microcrystalline cellulose opacode white s-1-18086 titanium dioxide - indicated in the treatment of patients with mild to moderately severe dementia of the alzheimer type, also termed probable alzheimers disease or alzheimers disease.

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - rivastigmine tartrate 9.6mg equivalent to 6 mg rivastigmine;   - capsule - 6 mg - active: rivastigmine tartrate 9.6mg equivalent to 6 mg rivastigmine   excipient: colloidal silicon dioxide gelatin   hypromellose iron oxide red   iron oxide yellow   magnesium stearate microcrystalline cellulose tekprint red sw-1102 titanium dioxide   - indicated in the treatment of patients with mild to moderately severe dementia of the alzheimer type, also termed probable alzheimers disease or alzheimers disease.

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - rivastigmine tartrate 3.2 mg/ml equivalent to 2 mg/ml rivastigmine base;   - oral solution - 2 mg/ml - active: rivastigmine tartrate 3.2 mg/ml equivalent to 2 mg/ml rivastigmine base   excipient: citric acid monohydrate purified water quinoline yellow sodium benzoate sodium citrate dihydrate - treatment of patients with mild to moderately severe dementia of the alzheimer type, also termed probable alzheimer's disease or alzheimer's disease.

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - rivastigmine 18mg;  ;   - transdermal patch - 9.5 mg/24h - active: rivastigmine 18mg     excipient: dimeticone dl-alpha tocopherol acrylic pressure sensitive adhesive silicone pressure sensitive adhesive backing film 10 cm square release liner 20.25 cm square poly(butyl methacrylate-co-methyl methacrylate) - treatment of patients with: · mild to moderately severe dementia of the alzheimer's type (also termed probable alzheimer's disease or alzheimer's disease) · severe dementia of the alzheimer's type.

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - rivastigmine 27mg;  ;   - transdermal patch - 13.3 mg/24h - active: rivastigmine 27mg     excipient: dimeticone dl-alpha tocopherol acrylic pressure sensitive adhesive silicone pressure sensitive adhesive backing film 15 cm square release liner 30.375 cm square poly(butyl methacrylate-co-methyl methacrylate) - treatment of patients with: · mild to moderately severe dementia of the alzheimer's type (also termed probable alzheimer's disease or alzheimer's disease) · severe dementia of the alzheimer's type.

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - rivastigmine 36mg;  ;   - transdermal patch - 17.4 mg/24h - active: rivastigmine 36mg     excipient: dimeticone dl-alpha tocopherol acrylic pressure sensitive adhesive silicone pressure sensitive adhesive backing film 20 cm square release liner 40.5 cm square poly(butyl methacrylate-co-methyl methacrylate) - treatment of patients with: · mild to moderately severe dementia of the alzheimer's type (also termed probable alzheimer's disease or alzheimer's disease) · severe dementia of the alzheimer's type.

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - rivastigmine 9mg;  ;   - transdermal patch - 4.6 mg/24h - active: rivastigmine 9mg     excipient: dimeticone dl-alpha tocopherol acrylic pressure sensitive adhesive silicone pressure sensitive adhesive backing film 5 cm square release liner 10.125 cm square poly(butyl methacrylate-co-methyl methacrylate) - treatment of patients with: · mild to moderately severe dementia of the alzheimer's type (also termed probable alzheimer's disease or alzheimer's disease) · severe dementia of the alzheimer's type.